Suven Pharmaceuticals Limited

Equities

SUVENPHAR

INE03QK01018

Pharmaceuticals

End-of-day quote NSE India S.E. 06:00:00 2024-07-14 pm EDT 5-day change 1st Jan Change
841.2 INR -0.82% Intraday chart for Suven Pharmaceuticals Limited +3.39% +16.37%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Suven Pharmaceuticals Acquires Majority Stake in Sapala Organics MT
Suven Pharmaceuticals Limited acquired 67.50% stake in Sapala Organics Private Limited for INR 2.3 billion. CI
Transcript : Sapala Organics Private Limited, Suven Pharmaceuticals Limited - M&A Call
Suven Pharmaceuticals to Acquire 67.5% Stake in Sapala Organics MT
Suven Pharmaceuticals Limited agreed to acquire 67.50% stake in Sapala Organics Private Limited for INR 2.3 billion. CI
Transcript : Suven Pharmaceuticals Limited, Q4 2024 Earnings Call, May 30, 2024
Suven Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
Suven Pharmaceuticals Limited Announces Shifting of Registered Office CI
Transcript : Cohance Lifesciences Limited, Suven Pharmaceuticals Limited - M&A Call
Indian shares set to rise on strong domestic growth, in-line US inflation data RE
Suven Pharmaceuticals Limited agreed to acquire Cohance Lifesciences Limited for INR 81,340.421103 million CI
US FDA Clears Suven Pharmaceuticals' API and Formulations Plants in Hyderabad, India MT
Suven Pharmaceuticals' Consolidated Net Profit Declines in Fiscal Q3 MT
Transcript : Suven Pharmaceuticals Limited, Q3 2024 Earnings Call, Feb 05, 2024
Suven Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Suven Pharmaceuticals CFO Steps Down MT
Suven Pharmaceuticals Limited Announces CFO Changes, Effective January 2, 2024 CI
Suven Pharmaceuticals Names CFO MT
Suven Pharmaceuticals Limited Appoints Dr. Vetukuri Venkata Naga Kali Vara Prasada Raju as Managing Director CI
Suven Pharmaceuticals Limited Announces Board Appointments CI
Suven Pharmaceuticals Limited Approves Interim Dividend for the Financial Year 2023-24 CI
Suven Pharmaceuticals Limited Proposes Interim Dividend for the Financial Year 2022-23 CI
Suven Pharmaceuticals Posts Gains in Fiscal Q2 Consolidated Profit MT
Suven Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Transcript : Suven Pharmaceuticals Limited, Q2 2024 Earnings Call, Nov 09, 2023
Chart Suven Pharmaceuticals Limited
More charts
Suven Pharmaceuticals Limited is an India-based company. The Company is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Specialty Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology, and chemical companies. The Company operates through Pharmaceuticals Manufacturing and Services segment. Its geographical segments include India, the United States, Europe, and others. In India, the Company sells bulk drugs and intermediates, chemicals, and services. In the United States, the Company sells intermediates and services. In Europe, the Company sells bulk drugs and intermediates. In other countries, the Company sells bulk drugs, intermediates, and services. The Company’s wholly owned subsidiary is Suven Pharma Inc.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
841.2 INR
Average target price
670.5 INR
Spread / Average Target
-20.29%
Consensus
  1. Stock Market
  2. Equities
  3. SUVENPHAR Stock
  4. News Suven Pharmaceuticals Limited
  5. Suven Pharmaceuticals to Acquire 67.5% Stake in Sapala Organics